Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biohaven (BHVN) Defended at William Blair
November 9, 2021 11:58 AM ESTWilliam Blair analyst Tim Lugo is out defending Biohaven Pharmaceutical Holding (NYSE: BHVN) on weakness after the company agreed to a strategic deal with Pfizer (NYSE: PFE) versus an outright takeover.
The analyst commented, "We view Nurtec ODT as the... More
Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States
November 9, 2021 7:47 AM ESTBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the third quarter ended September 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
NURTEC® ODT (rimegepant) continues to exceed expectations, reporting $136 million in net product revenue for the third quarter of 2021, totaling approximately $336 million in revenues and over 1,100,000 prescriptions from product launch to date - NURTEC ODT continues to be market leader for new oral migraine therapies and currently accounts for... MoreBiohaven Pharma (BHVN) Tops Q3 EPS by 49c; Reports Cash and Cash Equivalents of $523.9M
November 9, 2021 7:47 AM ESTBiohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.91), $0.49 better than the analyst estimate of ($2.40). Revenue for the quarter came in at $135.7 million versus the consensus estimate of $128.4 million.
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
... MoreBiohaven Pharma (BHVN) Halted, News Pending
November 9, 2021 7:24 AM ESTBiohaven Pharma (NYSE: BHVN) Halted, News Pending
